https://de.marketscreener.com/kurs/aktie/NEUROCRINE-BIOSCIENCES-IN-10163/news/Neurocrine-Biosciences-Inc-gibt-die-Verabreichung-des-ersten-Patienten-in-der-klinischen-Phase-2-S-46350995/?utm_source=telegram&utm_medium=social&utm_campaign=share